Rekor Systems' Q4 2025 Earnings Report: A Year of Progress and Growth

Rekor Systems' Q4 2025 Earnings Report: A Year of Progress and Growth


The latest quarterly earnings report from Rekor Systems, Inc. has revealed a year of significant progress and growth for the company.

According to CFO Joseph Nalepa, Rekor delivered top-line revenue growth in 2025, with total revenue reaching $48.5 million, a 5% increase compared to the previous year. This growth was driven by continued expansion across both public safety and urban mobility businesses.

The company's sales pipeline also showed strong momentum, with remaining performance obligations increasing by nearly 80% to $25.9 million as of December 31, 2025. This highlights Rekor's ability to drive growth into the new year.

Recurring revenue was also a key highlight for the quarter, reaching $23.9 million and representing a 6% year-over-year increase. This reflects Rekor's long-term strategy of expanding its recurring revenue base through software and data as a service subscription contracts.

The company's adjusted margin for 2025 reached 56%, compared to 49% in the previous year, driven by an increased portion of high-margin software sales relative to service and hardware-based contracts. Operational efficiencies within deployments also contributed to this improvement.

As Rekor continues to grow, it expects margins to fluctuate over time but stabilize as its software and data as a service businesses become a larger share of total revenue.

A key decision made by the company in 2025 was to onshore engineering efforts to optimize operations and contain costs. This move resulted in a non-cash asset impairment charge of $3.8 million, but is expected to yield long-term benefits for the business.

Total operating expenses declined 20% year-over-year, representing an $11.4 million reduction across all major areas of the business. The combination of revenue growth and improved operational efficiency led to significant profitability improvements, with adjusted EBITDA loss narrowing by $11 million or 38% compared to 2024.

The company's CFO highlighted that the trajectory of its adjusted EBITDA loss throughout 2025 demonstrates progress in implementing strategic realignment. As Rekor continues to evaluate operations and identify further efficiencies heading into 2026, it anticipates one-time charges related to the cancellation and restructuring of existing agreements, but views these as necessary steps towards building a leaner operating structure.

Read more

Imunon's Transformative Year: Groundbreaking IMNN-001 Results Set New Standard for Ovarian Cancer Treatment

Imunon's Transformative Year: Groundbreaking IMNN-001 Results Set New Standard for Ovarian Cancer Treatment

Imunon, a pioneering biotechnology company, made history with its fourth quarter and full year 2025 financial results, showcasing a truly transformational year in the fight against ovarian cancer. The company's proprietary IL-12 immunotherapy, IMNN-001, has demonstrated unprecedented potential to redefine frontline treatment for women with newly diagnosed advanced

By Mason Lankes